Primary Sclerosing Cholangitis

njemnu02826 alison56124 Jmac2 494 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Primary Sclerosing Cholangitis written for patients

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disorder characterised by inflammation and fibrosis of intrahepatic and extrahepatic bile ducts, resulting in multifocal biliary strictures. The cause of PSC remains unclear but hypotheses include genetic factors, lymphocyte recruitment and activation, portal bacteraemia and bile salt toxicity. Secondary sclerosing cholangitis includes conditions where infections, thrombosis, iatrogenic causes or trauma can give rise to similar clinical characteristics to PSC.[1] 

  • PSC is a rare disease with a prevalence of 0.2-16 per 100,000.
  • PSC commonly affects males with a median age at diagnosis of 35 years.
  • PSC accounts for 10% of all UK liver transplants.
  • There is a significant association with inflammatory bowel disease, hepatobiliary malignancies and colorectal cancer.[3] 

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »


  • May be asymptomatic (presenting with abnormal LFTs or hepatomegaly).
  • Jaundice and pruritus.
  • Right upper quadrant abdominal pain.
  • Fatigue, weight loss, fevers and sweats.
  • May present with complications (see 'Complications and their management', below).


  • Jaundice.
  • Hepatomegaly (may also have splenomegaly at presentation).

Later stages: signs of cirrhosis, portal hypertension or hepatic failure.


The Child-Turcotte-Pugh scale which is used to assess severity of disease includes:

  • Grade of encephalopathy.
  • Presence or absence of ascites.
  • Serum albumin level.
  • Prothrombin time.
  • Bilirubin level.
  • Vascular: hepatic artery thrombosis, portal hypertension biliopathy, portal cavernoma associated cholangiopathy, intra-arterial chemotherapy, sickle cell disease related cholangiopathy.
  • Trauma: trauma post-cholecystectomy, abdominal trauma.
  • Infections: AIDS-related cholangiopathy, recurrent pyogenic cholangitis.
  • Benign: intraductal stone disease.
  • Malignancy: cholangiocarcinoma.
  • Autoimmune: autoimmune sclerosing cholangitis, IgG4-related sclerosing cholangitis, systemic vasculitis.
  • Other: recurrent pancreatitis, sclerosing cholangitis in a critically ill patient, total parenteral nutrition-related cholangiopathy, histiocytosis X.

Blood tests

  • Abnormal LFTs are usual. The most common abnormality is elevation of alkaline phosphatase or gamma-glutamyltransferase (GGT) level.
  • Serum transaminase levels may be normal or elevated to several times normal.
  • Bilirubin is raised in advanced PSC.
  • Serum albumin and prothrombin time (PTT) become abnormal as the disease progresses.
  • Immunoglobulin G (IgG), IgM and the serum globulin fraction levels may be raised.
  • There may also be hypergammaglobulinaemia, raised IgM levels, perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), anticardiolipin (aCL) antibodies and antinuclear antibodies.

Other investigations

  • Ultrasound is the initial investigation and may show bile duct dilatation and liver and splenic changes; however, it is not diagnostic for PSC.
  • Magnetic resonance cholangiopancreatography (MRCP) is now the standard procedure to visualise the intrahepatic and extrahepatic bile ducts.
  • Endoscopic retrograde cholangiopancreatography (ERCP) or transhepatic cholangiography may also have a role but are invasive.
  • MRI may be useful to exclude other disease and evaluate the biliary system.
  • Liver biopsy is rarely diagnostic but may be useful for staging PSC.

Histological staging

There are four histological stages of the disease:

Stage 1: degeneration of the epithelial cells lining the bile ducts, associated with inflammatory cell ductal and periportal triad infiltration and scarring.
Stage 2: fibrosis, paucity of bile ductules, periportal inflammatory cell infiltration, and piecemeal necrosis of the periportal hepatocytes.
Stage 3: severe degenerative changes, with disappearance of the bile ducts, portal-to-portal fibrous septa, and periportal cholestasis.
Stage 4: end-stage disease with secondary biliary cirrhosis.

Despite years of research, medical treatments are only at best able to help manage symptoms.  Many drugs have been evaluated and found to be ineffective at halting progression of disease.[6] Liver transplantation remains the only life-prolonging treatment for patients with end-stage disease.[7] 


  • Treatment options for patients with cholestatic pruritus include the anion exchange resin colestyramine, rifampicin, the opioid antagonist naltrexone and the serotonin reuptake inhibitor sertraline.[8] 


  • As with other cholestatic disorders, supplements for the fat-soluble vitamins (vitamins A, D, E, K) may be required.
  • In children, nutritional support may be needed to ensure adequate growth.

Preventing progression

  • Systematic reviews have found no evidence of any benefit with either corticosteroids or penicillamine.[9][10] 
  • Ursodeoxycholic acid:
    • This gives a a significant improvement in liver biochemistry and is usually well tolerated.
    • However, it has not so far been shown to give any clinical benefit and high-dose ursodeoxycholic acid (28-30 mg/kg/day) has been shown to increase the adverse events rate.[6]
    • A Cochrane review concluded that there is insufficient evidence either to support or refute the use of bile acids in the treatment of PSC.[11]
  • Avoid alcohol, which is a risk factor for cholangiocarcinoma development.

Surgical and endoscopic interventions

  • Strictures causing recurrent cholangitis can be treated by balloon dilatation (endoscopic or percutaneous). Stents are also used.
  • Surgical drainage procedures are possible but do not alter prognosis because of the intrahepatic component of the disease. There is a postoperative risk of cholangitis and the procedures may make later transplantation more difficult.
  • Liver transplantation is an effective treatment. The indications for liver transplantation are similar to other causes of chronic liver disease but also include intractable pruritus and recurrent cholangitis.[1] 

Biliary complications

  • Biliary obstruction due to stones or strictures - treat with endoscopic or drainage procedures (see 'Surgical and endoscopic interventions', above).
  • Bacterial cholangitis, acute or chronic - treat with antibiotics.

Cirrhosis and associated complications

Related cancers

  • Cholangiocarcinoma and colorectal cancer are both increased in patients with PSC.[1] 
  • It has been recommended that:[12] 
    • Total colonoscopy with biopsies should be:
      • Performed in patients in whom the diagnosis of PSC has been established without known inflammatory bowel disease.
      • Repeated annually in PSC patients with colitis from the time of diagnosis of PSC.
    • Annual abdominal ultrasonography should be considered for gallbladder abnormalities.
  • PSC is a progressive disease of the liver characterised by inflammation and destruction of the intrahepatic and/or extrahepatic bile ducts, leading to fibrosis and ultimately liver failure, cirrhosis and an increased risk of malignancy.[13] 
  • PSC can be classified into small-duct or large-duct types, which seems to affect prognosis:[14]
    • Small-duct PSC has a better prognosis, with longer transplant-free survival.
    • Also, it appears that cholangiocarcinoma is unlikely with small-duct PSC.
  • Prognosis after liver transplant:
    • Survival post-transplant is about 94% 1 year, 86% at 5 years and 70% at 10 years.[1] 
    • However, liver transplantation does not guarantee a cure, with 20% recurrence in the graft.[2] 

Further reading & references

  1. Nayagam JS, Pereira SP, Devlin J, et al; Controversies in the management of primary sclerosing cholangitis. World J Hepatol. 2016 Feb 18;8(5):265-72. doi: 10.4254/wjh.v8.i5.265.
  2. Goode EC, Rushbrook SM; A review of the medical treatment of primary sclerosing cholangitis in the 21st century. Ther Adv Chronic Dis. 2016 Jan;7(1):68-85. doi: 10.1177/2040622315605821.
  3. Rizvi S, Eaton JE, Gores GJ; Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov;13(12):2152-65. doi: 10.1016/j.cgh.2015.05.035. Epub 2015 Jun 5.
  4. Lutz H, Trautwein C, Tischendorf JW; Primary sclerosing cholangitis: diagnosis and treatment. Dtsch Arztebl Int. 2013 Dec 23;110(51-52):867-74. doi: 10.3238/arztebl.2013.0867.
  5. Williamson KD, Chapman RW; Primary sclerosing cholangitis. Dig Dis. 2014;32(4):438-45. doi: 10.1159/000358150. Epub 2014 Jun 23.
  6. Sinakos E, Lindor K; Treatment options for primary sclerosing cholangitis. Expert Rev Gastroenterol Hepatol. 2010 Aug;4(4):473-88.
  7. Silveira MG, Lindor KD; Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol. 2008 Jun 7;14(21):3338-49.
  8. Kremer AE, Bolier R, van Dijk R, et al; Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis. 2014;32(5):637-45. doi: 10.1159/000360518. Epub 2014 Jul 14.
  9. Giljaca V, Poropat G, Stimac D, et al; Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD004036.
  10. Klingenberg SL, Chen W; D-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004182.
  11. Poropat G, Giljaca V, Stimac D, et al; Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011 Jan 19;(1):CD003626. doi: 10.1002/14651858.CD003626.pub2.
  12. Management of cholestatic liver diseases; European Association for the Study of the Liver (June 2009)
  13. Ali AH, Carey EJ, Lindor KD; Current research on the treatment of primary sclerosing cholangitis. Intractable Rare Dis Res. 2015 Feb;4(1):1-6. doi: 10.5582/irdr.2014.01018.
  14. Bjornsson E, Olsson R, Bergquist A, et al; The natural history of small-duct primary sclerosing cholangitis. Gastroenterology. 2008 Apr;134(4):975-80. Epub 2008 Jan 17.

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Naomi Hartree
Current Version:
Peer Reviewer:
Dr John Cox
Document ID:
1034 (v24)
Last Checked:
Next Review:

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for monthly healthcare and news updates.

We would love to hear your feedback!

Patient Access app - find out more Patient facebook page - Like our page